Therapy of genomic unstable solid tumours (WHO grade 3/4）in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial

INTRODUCTION: Neoantigens derived from tumour somatic mutations are recognised as ideal vaccine targets. Tumour neoantigens have been studied in a wide range of tumours. Most of research on neoantigens has focused just on a unique tumour and a single mutated gene. Currently, a few studies have repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ling, Tang, Jiaxi, Chen, Xia, Zhao, Juan, Tang, Wanyan, Liao, Bin, Nian, Weiqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189849/
https://www.ncbi.nlm.nih.gov/pubmed/35688598
http://dx.doi.org/10.1136/bmjopen-2021-055742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189849/
https://www.ncbi.nlm.nih.gov/pubmed/35688598
http://dx.doi.org/10.1136/bmjopen-2021-055742

Ejemplares similares